Long-term study of ralinepag for pulmonary hypertension
Part of Heart & circulation, Lungs & breathing, Skin clinical trials.
This study follows people with pulmonary arterial hypertension (PAH) to see how safe and effective ralinepag is over the long term. It may help your care team understand what to expect from continued treatment and monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign consent before any study steps begin
- You must be able to attend scheduled visits and lab tests, and follow the treatment plan
- You must have finished the prior ralinepag study’s end visit steps
- You must use reliable birth control during the study and for 30 days after your last dose (and not try to get pregnant)
- You must not have stopped ralinepag early in the last ralinepag study due to side effects or problems, and you must have completed required study visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people who have already taken part in a clinical trial of sotatercept for pulmonary arterial hypertension and done well enough to continue. It tests the long-term safety and effectiveness of staying on sotatercept, an investigational treatment that helps lower blood pressure in the lungs.
This study tests whether taking injected treprostinil together with riociguat can improve how the heart and lung blood vessels work in people with advanced pulmonary artery hypertension (PAH). It may help improve blood-flow measurements and the structure of the heart.
This trial is for people with pulmonary arterial hypertension (PAH) who have already completed a previous study of the drug seralutinib. It offers continued access to the treatment so doctors can watch its safety and effects over a longer time.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH). It aims to see if it can improve exercise ability and symptoms when added to your current PAH therapy.
This trial tests an experimental drug called HS235 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It aims to see if the drug can help improve symptoms and exercise ability.
This study tracks natural changes in “biomarkers” (measurable signals in blood) and imaging findings in people with pulmonary arterial hypertension (PAH) or suspected PAH. It also includes healthy people for comparison, helping researchers understand what these signals mean over time.
Hear when a new PAH trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.